Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07735039 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual-Modality Immunotherapy for HPV Clearance (DUAL-HPV)

Study acronym: DUAL-HPV
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 29, 2026 (before its estimated August 23, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Persistent high-risk human papillomavirus infection is an important precursor of cervical cancer and related cervical lesions. This single-center, randomized, assessor-blinded, parallel-group controlled trial evaluates whether dual-modality immunotherapy consisting of an oral immunomodulator plus a vaginal ovule improves HPV clearance compared with standard supportive care. A total of 76 participants will be randomized in a 1:1 ratio. The primary outcome is HPV clearance confirmed by repeat HPV testing and cervical cytology after the 3-month treatment period. Treatment adherence and adverse events will also be monitored.
Trial Details
NCT Number NCT07735039
Lead Sponsor Dr. Lutfi Kirdar Kartal Training and Research Hospital
Conditions
(from sponsor)		 Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia (CIN), Low-Grade Squamous Intraepithelial Lesions
Related terms Atypical Squamous Cells of the Cervix, Papillomavirus Infections, Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia
Enrollment 76 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov